The approved dose is 300 mg by subcutaneous injection every four weeks. "The EU approval of Xolair in CSU is truly exciting for patients with this chronic and debilitating skin disease," said ...

Participants in stage one were assigned to receive placebo or Xolair injections every two or four ... a GlobalData owned brand. The information on this site has been included in good faith for ...

Omalizumab is generally well tolerated in adults and children with allergic asthma. Adverse events most commonly observed are injection-site reaction, viral infection, upper-respiratory-tract ...

Joshua Cohen is a Boston-based writer who covers health policy. Two weeks ago, the Food and Drug Administration approved Xolair (omalizumab) for immunoglobulin E-mediated food allergy in certain ...